Moderna Inc. ($MRNA) Stock Forecast: Up 8.6% Today

What is Moderna Inc.?

Moderna is a renowned pharmaceutical company known for its innovative mRNA technology in vaccine development. The company has been at the forefront of combating various diseases, including Covid-19.

Why is Moderna Inc. going up?

MRNA stock is up 8.6% on Feb 12, 2026 15:07

• Moderna's stock experienced a strong bullish movement following the news of a five-year agreement with Mexico to enhance mRNA vaccine supply for respiratory diseases. This collaboration not only expands Moderna's market reach but also signifies its commitment to global health initiatives.
• The FDA's rejection of Moderna's flu vaccine application might have initially caused some uncertainty in the market. However, the positive development with Mexico and the focus on respiratory vaccines could have overshadowed this setback, driving the bullish momentum.
• The market seems to be reacting favorably to Moderna's strategic partnerships and long-term growth prospects, positioning the company as a key player in the biotech industry. Investors are likely viewing Moderna as a solid investment choice amidst ongoing advancements in medical technology and global health priorities.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

The Truth About Novavax Inc (NVAX): Comeback Story or Total Bag Fumble?

This article examines Novavax Inc (NVAX) to determine if it's a potential comeback story or a high-risk investment. It discusses the mixed sentiment around the stock, its protein-based vaccine technology, and its volatility. The piece concludes that NVAX is a speculative play for risk-tolerant investors rather than a core portfolio holding.

https://www.ad-hoc-news.de/boerse/news/ueberblick/the-truth-about-novavax-inc-nvax-comeback-story-or-total-bag-fumble/68573971

BioNTech SE Just Flipped The Script: Is BNTX The Next Big ‘Must-Cop’ or a Total Trap?

BioNTech SE, known for its pivotal role in pandemic vaccines, is now focusing on applying its mRNA technology to cancer and infectious disease treatments. While its stock (BNTX) has seen a significant drop from its pandemic peak, the article suggests it's a potential high-risk, high-reward investment for long-term believers in biotech's future, rather than a quick win for short-term traders. The company is positioned as a deep science player in contrast to its flashier competitor, Moderna, making it a "must-watch" for those betting on future medical advancements.

https://www.ad-hoc-news.de/boerse/news/ueberblick/biontech-se-just-flipped-the-script-is-bntx-the-next-big-must-cop/68573726

Mexico enlists Moderna to boost mRNA supply for respiratory diseases

Mexico has signed a five-year agreement with Moderna to bolster its mRNA vaccine supply for respiratory diseases. The deal involves Moderna supplying its respiratory vaccine portfolio and transferring its Covid-19 vaccine technology to Mexican pharma company Liomont, enabling local production. This initiative, part of Mexico's "Plan Mexico" for economic growth and local production capacity, contrasts with recent US regulatory resistance to Moderna's mRNA flu vaccine candidate.

https://www.pharmaceutical-technology.com/news/mexico-enlists-moderna-to-boost-mrna-supply-for-respiratory-diseases/

Stocks to Watch Wednesday: Netflix, QXO, Moderna, SLB -- WSJ

This article lists several stocks to watch on Wednesday, including Netflix, QXO, Moderna, and SLB. It specifically highlights Unity Software's (U.US) fourth-quarter earnings, noting that its revenue increased 35% year-over-year to $609 million, surpassing the consensus estimate. The company, however, reported a quarterly loss of 66 cents per share.

https://news.futunn.com/en/post/68773619/stocks-to-watch-wednesday-netflix-qxo-moderna-slb-wsj

Money Matters: FDA rejects Moderna's flu vaccine application, Hershey's offering chocolate Olympic medals

The article "Money Matters" reports on two distinct news items. Firstly, the FDA rejected Moderna's application for a flu vaccine, indicating a setback for the pharmaceutical company. Secondly, Hershey's is embracing the Olympic spirit by offering chocolate Olympic medals, suggesting a new marketing initiative or product offering.

https://www.clickorlando.com/video/news/2026/02/11/money-matters-fda-rejects-moderna-s-flu-vaccine-application-hershey-s-offering-chocolate-olympic-medals/

Trending Today

POL (Polygon) ($POL) Crypto Forecast: Up 8.8% Today

Silver ($XAG) Commodity Forecast: Down 8.3% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Down 5.1% Today

Iron Mountain Incorporated (Delaware)Common Stock REIT ($IRM) Stock Forecast: Up 5.2% Today

Marathon Petroleum Corporation ($MPC) Stock Forecast: Down 5.2% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Down 5.1% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Down 5.0% Today

Gartner Inc. ($IT) Stock Forecast: Down 5.1% Today

CBRE Group Inc Class A ($CBRE) Stock Forecast: Down 8.3% Today

Lincoln National Corporation ($LNC) Stock Forecast: Up 5.4% Today

Moderna Inc. Price History

30.00.2026 - MRNA Stock was down 5.4%

• A recent partnership for the development of mRNA-3927 for propionic acidemia highlights Moderna's dedication to broadening its portfolio beyond vaccines.
• The appointment of Dr. David Berman as Chief Development Officer brings valuable expertise in immunotherapy, potentially indicating a shift towards advancing clinical-stage therapies.
• Despite recent positive developments, concerns over financial pressures and an ambitious profitability target set for 2028 have led to a bearish market reaction.
• Investors may be cautious about the leadership transition from Dr. Jacqueline Miller to Dr. David Berman, as such changes can introduce uncertainties impacting stock performance.

30.00.2026 - MRNA Stock was down 5.7%

• Moderna's stock experienced a bearish movement following the announcement of the departure of its chief medical officer amidst other executive departures within the company.
• The appointment of Dr. David Berman as the new Chief Development Officer was not enough to offset the negative sentiment, as investors may be concerned about the leadership changes and potential impact on the company's future direction.
• The partnership with Recordati to develop an mRNA therapy for a rare metabolic disorder was a positive development, but it seems the market focused more on the internal leadership changes at Moderna.
• The overall market reaction suggests that investors are closely monitoring Moderna's executive team transitions and the company's ability to maintain its innovative edge in mRNA technology amidst leadership shake-ups.

11.01.2026 - MRNA Stock was down 9.3%

• A recent FDA decision on Moderna's flu vaccine application is seen as a setback for the company's vaccine pipeline, potentially influencing the bearish movement in the stock.
• However, the acceptance of mRNA-1010 for review in various regions such as the EU, Canada, and Australia may offer some comfort to investors, mitigating the overall impact on Moderna's financial prospects.
• The company's new five-year vaccine agreement with the Mexican government has the potential to counterbalance the negative sentiment from the FDA decision, indicating a strategic move for revenue growth and expansion into new markets.
• The market's response to Moderna's bearish trend today may reflect the varied reports on its vaccine developments and collaborations, with investors keen on monitoring the firm's regulatory advancements and commercial ventures in the future.

11.01.2026 - MRNA Stock was down 15.2%

• The FDA rejection of Moderna's flu vaccine application likely contributed to the bearish movement in MRNA stock. This setback could have raised concerns among investors about the company's pipeline and future revenue streams.
• Despite the FDA rejection, Moderna's strategic agreements with the Mexican government and local pharmaceutical companies could provide a potential revenue boost in the long term. However, the immediate market reaction seems to have been overshadowed by the negative news of the flu vaccine application rejection.
• The news of Moderna's acceptance for review in other regions like the EU, Canada, and Australia might have mitigated some of the stock's losses, indicating potential global market opportunities for the company.
• Overall, the market movement in MRNA today reflects a mix of regulatory challenges and strategic partnerships, showcasing the volatility and resilience of the biopharmaceutical sector.

06.01.2026 - MRNA Stock was down 6.1%

• The stock experienced a bearish movement, possibly due to the anticipation of its upcoming quarterly earnings projecting a loss per share and lower revenue than expected.
• Recent insider selling activity might have also contributed to the negative sentiment surrounding the stock.
• The launch of leveraged ETFs tied to the company's share prices could have amplified the downward pressure on the stock as traders adjusted their positions based on market volatility and risk factors associated with leveraged products.

05.01.2026 - MRNA Stock was down 6.2%

• Moderna's stock experienced a bearish movement possibly due to legal uncertainties surrounding its mRNA vaccine technology in the Arbutus v. Moderna patent infringement case.
• The market may have reacted negatively to the summary judgment rulings issued by Judge Wolson, which could impact Moderna's vaccine sales and ongoing legal battles.
• Despite advancements in oncology and promising clinical trial results in the industry, the specific legal challenges faced by Moderna might have overshadowed positive developments in the broader healthcare sector.
• Investors might be cautious about the implications of the legal proceedings on Moderna's revenue and market position, leading to the bearish movement in the stock price.

10.01.2026 - MRNA Stock was up 8.9%

• Today, Moderna's positive stock movement is linked to the favorable investor sentiment surrounding its advancements in cancer vaccine development and its overall market success.
• A strategic partnership with Mexico to bolster vaccine manufacturing capacity and provide respiratory vaccines has likely instilled confidence in investors regarding Moderna's growth prospects.
• Endorsement by Jim Cramer as a top-performing stock of the year has also bolstered Moderna's positive momentum, showcasing its resilience and future potential.
• Projected revenue growth in 2026 and ongoing research and development endeavors by key players in the biotechnology sector, including Moderna, point towards a promising outlook for the company's future performance.

10.01.2026 - MRNA Stock was up 5.4%

• Moderna's positive performance today is linked to the strategic agreement reached with Mexico, which not only strengthens its global presence but also augments its revenue potential.
• Despite initial concerns stemming from a Sell rating and low price target by Bank of America Securities, news of the partnership with Mexico overshadowed these sentiments, boosting investor confidence.
• Collaborations such as the one with Recordati to advance investigational therapeutics highlight Moderna's diversification efforts beyond COVID-19 vaccines, further bolstering its long-term growth outlook.
• The overall optimistic trend in the biotechnology sector, especially within the United States market poised for significant advancements, likely contributed to the favorable stance on Moderna's stock today.

10.01.2026 - MRNA Stock was up 5.4%

• Moderna saw a surge in its stock value today due to recent strategic partnerships and agreements with the Mexican government. These initiatives aim to expand geographically, bolster local vaccine production, and fortify its position in global markets.
• The favorable reception from investors towards Moderna, acknowledged by notable market analysts, has also contributed to its upward movement as one of the standout stocks presently. Investor enthusiasm is fueled by Moderna's growth trajectory and promising ventures in cancer vaccines.
• Market response indicates a strong belief in Moderna's future revenue growth forecasts and its dedication to improving pandemic readiness and public health responses, exemplified by collaborations such as the one with Mexico.
• In essence, Moderna's positive market performance today reflects a blend of well-thought-out business strategies and optimistic market sentiment towards the company's expansion plans and groundbreaking vaccine technologies.

02.01.2026 - MRNA Stock was up 5.3%

• Moderna's upward momentum can be associated with the encouraging insights shared during the 44th Annual J.P. Morgan Healthcare Conference. The company emphasized its strategic business expansion, progress in product development, and anticipated financial performance over the upcoming years.
• The market responded positively to Moderna's detailed three-year business plan revealed during its Analyst Day. The plan included forecasts for revenue growth, expansion of its vaccine portfolio, and a heightened focus on oncology and rare disease treatments.
• Investors seemingly responded to Moderna's growth potential, despite concerns raised regarding declining revenue and projected performance compared to industry standards. The optimistic narrative presented by Moderna during recent conferences likely overshadowed these underlying challenges in the near term.

12.01.2026 - MRNA Stock was up 8.6%

• Moderna's stock experienced a strong bullish movement following the news of a five-year agreement with Mexico to enhance mRNA vaccine supply for respiratory diseases. This collaboration not only expands Moderna's market reach but also signifies its commitment to global health initiatives.
• The FDA's rejection of Moderna's flu vaccine application might have initially caused some uncertainty in the market. However, the positive development with Mexico and the focus on respiratory vaccines could have overshadowed this setback, driving the bullish momentum.
• The market seems to be reacting favorably to Moderna's strategic partnerships and long-term growth prospects, positioning the company as a key player in the biotech industry. Investors are likely viewing Moderna as a solid investment choice amidst ongoing advancements in medical technology and global health priorities.

03.01.2026 - MRNA Stock was down 7.0%

• Despite a positive performance over the past year and year-to-date, Moderna's stock witnessed a bearish movement today. This comes in light of successful partnerships and promising experimental vaccines.
• The robust financial results and pipeline progress of Merck & Co. may have diverted investor attention from Moderna, impacting MRNA's stock adversely.
• Moderna's announcement of an upcoming webinar on decision intelligence for an autonomous cold chain underscores its dedication to innovation. However, this development might not have been sufficient to counter the prevailing market sentiment affecting MRNA's stock.
• The FDA's recent request for monitoring myocarditis in a new COVID antibody trial possibly added to market uncertainty. This factor could have influenced the bearish movement in Moderna's stock observed today.